Loading stock data…
KRYS
$286.95+20.91 (+7.86%)
Market ClosedLast close May 4
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Krystal Biotech, Inc. in the Healthcare sector is trading at $286.95. The stock is currently near its 52-week high of $298.30, remaining 31.4% above its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why KRYS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$286.95
Potential Downside
49.3%
Whystock Fair Value$145.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$315.00+9.8%
Range$241.00 – $380.00
Fundamentals
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremag...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.28
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.03%
Volume
Today's trading volume
651,427
Recent News
Krystal Biotech, Inc. Q1 2026 Earnings Call Summary
Moby summary of Krystal Biotech, Inc.'s Q1 2026 earnings call
Krystal (KRYS) Q1 2025 Earnings Transcript
Krish Krishnan: Thank you, Stephane. VYJUVEK going global, the upcoming clinical readouts in 2025, primarily CF Alpha-1, a very exciting second ophthalmic program to treat neurotrophic keratitis that just entered the clinic, and briefly discuss in the end how Krystal's insulated in the current macro and FDA situation. With the positive EC decision now behind us and the broad label that we were fortunate to receive, we're excited about launching in Europe where the burden of finding genetically confirmed patients is much lower than it has been in the U.S. We would like to highlight that this is a full approval and not a conditional approval, now that's pretty rare, and we do not have any post-approval efficacy study requirements with respect to the EU.
Krystal Biotech Q1 Earnings Call Highlights
Krystal Biotech (NASDAQ:KRYS) reported first-quarter 2026 net revenue of $116.4 million from global sales of VYJUVEK, supported by continued demand in the U.S. and early traction in Europe and Japan. Management highlighted positive operating leverage, a 95% gross margin, and an expanding clinical pi
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +26.21% and +3.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage Pipeline
Analysts have been lifting fair value estimates for Krystal Biotech, with the updated Street number moving from US$291.22 to US$315.00, roughly a US$24 shift in the latest models. That change lines up with recent research that links price targets in the US$280 to US$370 range to views on Vyjuvek assumptions, FY25 forecasts, and how much credit to give the late stage pipeline. As you read on, you will see how to track these evolving calls so you can keep your own Krystal Biotech view...